tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Karyopharm assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Robert Burns assumed coverage of Karyopharm (KPTI) with a Buy rating and $27 price target The firm believes the company’s investigation into maintenance therapy for the solid tumor indication is “risk-mitigated.” Karyopharmhas “several significant data catalysts” that could drive investor interest, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1